Systems and methods relating to medical applications of inverse thermosensitive polymer foam formulations
Disclosed herein is a pressurized therapeutic composition configured to be stored in a valved container designed to maintain an inverse thermosensitive polymer foam composition under pressure and dispense the composition upon opening the valve thereof. After the composition is dispensed from the container the evaporation of an expanding component (e.g., compressed gas or volatile liquid) can cause the inverse thermosensitive polymer solution to foam. The reduced pressure produced from dispensing the inverse thermosensitive polymer solution can reduce its temperature so as to facilitate distribution in a more liquid foam form. The inverse thermosensitive polymer solution can undergo a reverse phase change from a liquid to a gel upon warming (e.g., once dispensed onto or into a body part).
1. A pressurized inverse thermosensitive polymer foam formulation configured to be stored in a valved container designed to maintain the formulation under pressure and dispense the formulation upon opening a valve of the valved container, the formulation comprising:
an aqueous solution of a copolymer of ethylene oxide and propylene oxide, wherein the aqueous solution is configured to undergo a reverse phase change from a liquid to a gel;
one or more antibiotics, the one or more antibiotics including vancomycin at a concentration between about 0.1% w/w/to about 6.0% w/w;
a preservative;
a pH adjuster; and
an expanding component that is a liquified hydrofluorocarbon gas, wherein
the formulation comprises a stable and macroscopically homogenous solution,
the formulation is configured to be deployed from the container such that the liquified hydrofluorocarbon gas causes the formulation to foam after the formulation is dispensed from the container,
the formulation is configured to be applied topically, and
the formulation is configured to initially be deployed from the container at a lower viscosity to spread more easily and becomes more viscous upon contact with the body.
2. The pressurized inverse thermosensitive polymer foam formulation of claim 1 , further comprising a humectant.
3. The pressurized inverse thermosensitive polymer foam formulation of claim 1 , wherein the preservative is phenoxyethanol.
4. The pressurized inverse thermosensitive polymer foam formulation of claim 1 , wherein the pH adjuster is a phosphate buffer.
5. The pressurized inverse thermosensitive polymer foam formulation of claim 1 , wherein the pH adjuster results in a pH of the formulation of about 6.25 to 6.75.
6. A pressurized valve container, comprising:
a container including a valve;
a pressurized inverse thermosensitive polymer foam formulation stored in the container, the container configured to maintain the formulation under pressure and dispense the formulation upon opening the valve, the formulation comprising:
an aqueous solution of a copolymer of ethylene oxide and propylene oxide, wherein the aqueous solution is configured to undergo a reverse phase change from a liquid to a gel;
one or more antibiotics, the one or more antibiotics including vancomycin at a concentration between about 0.1% w/w to about 6.0% w/w;
a preservative;
a pH adjuster; and
an expanding component that is a liquified hydrofluorocarbon gas, wherein
the formulation comprises a stable and macroscopically homogenous solution,
wherein the container is configured to deploy the formulation such that the liquified hydrofluorocarbon gas causes the formulation to foam after the formulation is dispensed from the container,
the formulation is configured to be applied topically following deployment from the container,
and
the formulation is configured to initially be deployed from the container at a lower viscosity to spread more easily and becomes more viscous upon contact with the body.
7. The pressurized valved container of claim 6 , further comprising a piston separating the pressurized inverse thermosensitive polymer foam formulation from a driving gas.
8. The pressurized valved container of claim 7 , wherein the driving gas is the same liquified hydrofluorocarbon gas as the expanding component.
9. The pressurized valved container of claim 6 , further comprising an applicator tip including a spreader configured to disperse the foam over a surface area.
10. The pressurized inverse thermosensitive polymer foam formulation of claim 1 , wherein the one or more antibiotics further includes one or more of the following: cephalosporin, aminoglycoside, glycopeptide, fluroquinolone, bacitracin, doxycycline, minocycline, neomycin, and thymol.
11. The pressurized inverse thermosensitive polymer foam formulation of claim 1 , wherein the one or more antibiotics includes gentamicin or tobramycin at a concentration between about 0.1% w/w to about 2% w/w.
12. The pressurized inverse thermosensitive polymer foam formulation of claim 1 , wherein the one or more antibiotics includes both vancomycin and an aminoglycoside.
13. The pressurized inverse thermosensitive polymer foam formulation of claim 12 , wherein the aminoglycoside has a concentration between about 0.1% w/w to about 2% w/w.
14. The pressurized inverse thermosensitive polymer foam formulation of claim 1 , wherein the one or more antibiotics is stabilized by one or more components of the rest of the inverse thermosensitive polymer foam formulation.
15. The pressurized inverse thermosensitive polymer foam formulation of claim 2 , wherein the humectant is glycerin.